Induction of 100‐point clinical response · induction of remission in Crohn's disease
GM‐CSF showed no clear difference in induction of 100‐point clinical response compared with placebo (low certainty).
1 finding from 1 review
Induction of 70‐point clinical response CDAI · induction of remission in Crohn's disease
GM‐CSF showed no clear difference in induction of 70‐point clinical response compared with placebo (low certainty).
1 finding from 1 review
Adverse events · induction of remission in Crohn's disease
GM‐CSF showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · induction of remission in Crohn's disease
GM‐CSF showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Complete remission (CDAI<150 with a decrease in CDAI of at least 100 points from baseline) · induction of remission in Crohn's disease
IL‐10 showed no clear difference in complete remission (CDAI<150 with a decrease in CDAI of at least 100… compared with placebo (moderate certainty).
1 finding from 1 review
CDAI <150 at 24 weeks · induction of remission in Crohn's disease
IL‐10 showed no clear difference in clinical remision (CDAI<150) compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawls due to adverse events · induction of remission in Crohn's disease
IL‐10 probably leads to higher withdrawls due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Clinical remission · Induction of Remission in Medically Refractory Crohn's Disease
Summary of findings table ‐ Stem Cell showed no clear difference in clinical remission compared with placebo or Control (low certainty).
1 finding from 1 review
CDAI <150 at 24 weeks · Induction of Remission in Medically Refractory Crohn's Disease
It is very uncertain whether summary of findings table ‐ Stem Cell changes CDAI <150 at 24 weeks compared with placebo or Control (very low certainty).
1 finding from 1 review
Fistula Closure short‐term · Induction of Remission in Medically Refractory Crohn's Disease
Summary of findings table ‐ Stem Cell may leads to higher fistula Closure short‐term compared with placebo or Control (low certainty).
1 finding from 1 review
Fistula closure in long‐term · Induction of Remission in Medically Refractory Crohn's Disease
Summary of findings table ‐ Stem Cell may leads to higher fistula closure in long‐term compared with placebo or Control (low certainty).
1 finding from 1 review
Total adverse events · Induction of Remission in Medically Refractory Crohn's Disease
It is very uncertain whether summary of findings table ‐ Stem Cell changes total Adverse Events compared with placebo or Control (very low certainty).
1 finding from 1 review
Serious adverse events · Induction of Remission in Medically Refractory Crohn's Disease
Summary of findings table ‐ Stem Cell showed no clear difference in serious Adverse Events compared with placebo or Control (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Induction of Remission in Medically Refractory Crohn's Disease
It is very uncertain whether summary of findings table ‐ Stem Cell changes withdrawal due to adverse events compared with placebo or Control (very low certainty).
1 finding from 1 review
Failure to maintain clinical remission at end of study · people with Crohn's disease who responded to CZP remission‐induction treatment
Certolizumab pegol probably leads to lower failure to maintain clinical remission at week 26(1 RCT, 428… compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.73 [0.63, 0.85]
Studies not reported
Moderate
Failure to maintain clinical response · people with Crohn's disease who responded to CZP remission‐induction treatment
Certolizumab pegol probably leads to lower failure to maintain clinical response at week 26(1 RCT, 428… compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.58 [0.48, 0.71]
Studies not reported
Moderate
Any severe adverse event during maintenance treatment · people with Crohn's disease who responded to CZP remission‐induction treatment
Certolizumab pegol showed no clear difference in serious adverse events during remission maintenance treatment(1 RCT,… compared with placebo (low certainty).
1 finding from 1 review
RR 0.84 [0.4, 1.78]
Studies not reported
Low
Recurrence · adult participants (> 16 years of age) undergoing intestinal resection due to Crohn's disease
Intensification of prophylactic therapy guided by colonoscopy showed no clear difference in clinical recurrence ( compared with intensification guided by clinical recurrence (low certainty).
1 finding from 1 review
Mortality ( · adult participants (> 16 years of age) undergoing intestinal resection due to Crohn's disease
1 finding from 1 review
Quality of life · adult participants (> 16 years of age) undergoing intestinal resection due to Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found